BILL ANALYSIS

HR3164

NEUTRAL

Ensuring Community Access to Pharmacist Services Act

HR3164 (Ensuring Community Access to Pharmacist Services Act) has been assessed with a neutral outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

neutral

Market Sentiment

4/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

HR3164 is in early legislative stage with no funding mechanism; near-term revenue impact is zero.

CVS and WBA could be long-term beneficiaries if the bill passes with funding, but no immediate catalyst.

CVS's recent price strength (+5.85% 7-day) is due to sector momentum, not this bill.

How HR3164 Affects the Market

The healthcare sector has seen broad gains recently, with CVS up 5.85% in 7 days and 10.43% in 30 days. However, this movement is disconnected from HR3164's legislative progress. The bill's 117 cosponsors indicate bipartisan support, but without a funding mechanism, the market impact remains speculative. Investors should watch for floor action and potential amendments that include appropriations before adjusting positions in CVS or WBA.

Bill Details

Metric	Value
Bill Number	HR3164
Market Sentiment	neutral
Event Date	May 21, 2026
Affected Sectors	Healthcare
Source	View on Congress.gov →

Summary

HR3164 expands Medicare Part B to cover pharmacist services but has no funding mechanism and remains in early legislative stage. CVS's recent 5.85% 7-day gain is driven by broader healthcare sector momentum, not this bill.

Full AI Market Analysis

HR3164 (Ensuring Community Access to Pharmacist Services Act) was introduced on May 1, 2025, and reported out of the House Energy and Commerce and Ways and Means committees via voice vote on May 21, 2026. It now awaits floor action. The bill would amend the Social Security Act to cover pharmacist services under Medicare Part B for evaluation/management visits and testing/treatment of COVID-19, influenza, RSV, and streptococcal pharyngitis, as well as services during declared public health emergencies. However, the bill does not include any funding mechanism or appropriation—it merely authorizes coverage, meaning any actual spending would require separate appropriations. With 117 cosponsors and bipartisan support, the bill has momentum, but its early stage and lack of direct funding limit near-term revenue impact. The most direct beneficiaries are retail pharmacy chains with large clinic networks, such as CVS (operator of MinuteClinic) and Walgreens Boots Alliance (WBA). For CVS, the company's FY2025 revenue of $372.6B (based on SEC filings) dwarfs any potential new service revenue, making the impact immaterial. Current market data shows CVS at $95.92, up 5.85% over 7 days and 10.43% over 30 days, but these moves align with sector-wide advances in healthcare (e.g., UNH, JNJ) rather than specific bill progress. The next legislative step is a House floor vote, followed by Senate consideration (with companion bill S2426). Given the procedural status, no material market impact is expected until funding is attached.